<bill session="115" type="h" number="5926" updated="2023-01-11T13:39:27Z">
  <state datetime="2018-05-23">REFERRED</state>
  <status>
    <introduced datetime="2018-05-23"/>
  </status>
  <introduced datetime="2018-05-23"/>
  <titles>
    <title type="display">Naloxone Guidelines Act of 2018</title>
    <title type="official" as="introduced">To require the Secretary of Health and Human Services to issue guidelines for prescribing naloxone, and for other purposes.</title>
    <title type="short" as="introduced">Naloxone Guidelines Act of 2018</title>
  </titles>
  <sponsor bioguide_id="K000375"/>
  <cosponsors>
    <cosponsor bioguide_id="R000598" joined="2018-05-23"/>
  </cosponsors>
  <actions>
    <action datetime="2018-05-23">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-05-23" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="115" type="h" number="6" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug therapy"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Health promotion and preventive care"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2019-03-19T22:50:07Z" status="Introduced in House">Naloxone Guidelines Act of 2018

This bill requires the Department of Health and Human Services to issue guidelines for prescribing an opioid overdose reversal drug (e.g., naloxone).

The guidelines must address issues relating to the distribution, education, and safety of opioid overdose reversal drugs, including:

 co-prescription with an opioid; safe dosages; prescription for non-patients; and standing orders (i.e., orders that allow dispensing without a prescription).</summary>
</bill>
